Ergenç İlkay, Şanal Toprak Canan, Odabaşı Zekaver
Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey.
Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey.
Turk J Phys Med Rehabil. 2021 Sep 1;67(3):382-385. doi: 10.5606/tftrd.2021.8208. eCollection 2021 Sep.
Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
2019冠状病毒病（COVID-19）是一场全球大流行疾病，对全球健康构成威胁。高达15%的确诊病例会发展为重症疾病，需要住院治疗或入住重症监护病房（ICU）。托珠单抗是一种白细胞介素-6受体拮抗剂，是治疗COVID-19过程中出现的伴有急性呼吸窘迫综合征（ARDS）或细胞因子释放综合征（CRS）的重症肺炎的一种有前景的治疗方法。我们报告了一例在接受托珠单抗治疗的重症COVID-19患者中发生的化脓性肋软骨炎和胸壁脓肿。
